Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza.
about
Influenza and the use of oseltamivir in childrenPeramivir injection in the treatment of acute influenza: a review of the literaturePlasma concentrations of oseltamivir and oseltamivir carboxylate in critically ill children on extracorporeal membrane oxygenation supportUse of intravenous peramivir for treatment of severe influenza A(H1N1)pdm09Antibiotic therapy of pneumonia in the obese patient: dosing and deliveryReview on the impact of pregnancy and obesity on influenza virus infectionThe pharmacological management of severe influenza infection - 'existing and emerging therapies'.Pharmacokinetics of orally administered oseltamivir in healthy obese and nonobese Thai subjects.Early emergence of an H275Y mutation in a hematopoietic cell transplant recipient treated with intravenous peramivir.Use of early corticosteroid therapy on ICU admission in patients affected by severe pandemic (H1N1)v influenza A infection.A novel risk factor for a novel virus: obesity and 2009 pandemic influenza A (H1N1).Oseltamivir and oseltamivir carboxylate pharmacokinetics in obese adults: dose modification for weight is not necessary.Triple-combination antiviral drug for pandemic H1N1 influenza virus infection in critically ill patients on mechanical ventilation.Peramivir use for treatment of hospitalized patients with influenza A(H1N1)pdm09 under emergency use authorization, October 2009-June 2010.The first, second and third wave of pandemic influenza A (H1N1)pdm09 in North Denmark Region 2009-2011: a population-based study of hospitalizations.Pandemic Influenza A H1N1 (2009) Virus: Lessons from the Past and Implications for the Future.The use of antiviral drugs for influenza: Guidance for practitioners 2012/2013High levels and safety of oseltamivir carboxylate plasma concentrations after nasogastric administration in critically ill children in a pediatric intensive care unit.Acute respiratory distress syndrome caused by influenza B virus infection in a patient with diffuse large B-cell lymphoma.Safety, tolerability, and pharmacokinetics of intravenous oseltamivir: single- and multiple-dose phase I studies with healthy volunteersPopulation pharmacokinetics of oseltamivir and oseltamivir carboxylate in obese and non-obese volunteers.Pharmacokinetic properties of anti-influenza neuraminidase inhibitors.Antiplatelet Therapy Considerations in Ischemic Cardiogenic Shock: Implications of Metabolic Bioactivation.Therapeutic drug monitoring of anti-infective agents in critically ill patients.Transplacental transfer of oseltamivir phosphate and its metabolite oseltamivir carboxylate using the ex vivo human placenta perfusion model in Chinese Hans population.Comparison of High-Dose Versus Standard Dose Oseltamivir in Critically Ill Patients With Influenza.Severe viral pneumonia in adults: what is important for the ICU physician?Pharmacokinetics of Oral and Intravenous Oseltamivir Treatment of Severe Influenza B Virus Infection Requiring Organ Replacement Therapy.Peramivir is as effective as oral oseltamivir in the treatment of severe seasonal influenza.A part-randomized study of intravenous oseltamivir in adolescents and adults.High-dose versus standard dose oseltamivir for treatment of severe influenza in adult intensive care unit patients.Oseltamivir Dosing in Critically Ill Patients With Severe Influenza.Zika virus like particles elicit protective antibodies in mice.Pharmacokinetics of oseltamivir and oseltamivir carboxylate in critically ill patients receiving continuous venovenous hemodialysis and/or extracorporeal membrane oxygenation.Pandemic influenza A (H1N1) 2009-associated hemolytic uremic syndrome
P2860
Q26739661-C7978B92-1DB3-4D6F-87F8-E8908AC703D8Q28068310-D9820092-66AD-472A-AA69-8BC23B628C4CQ28474209-368A210D-1C8A-4578-BE2A-EEEA354E89E8Q28480880-68659347-C003-485B-B8D4-E4EE6A1211DFQ29248400-8A0364B8-9D3E-4542-AFE8-894A573E0C5DQ30224744-30582947-C796-4C71-83C0-84AF4556A426Q30243907-26C86B22-07C3-401A-B8C9-08076FC42F85Q30357189-27FC769B-5287-4E6C-B2FF-3D74A3AFF9E5Q30396031-B2BCE1F0-E3CC-4FD2-96FA-265106C01885Q30396672-D193A0D3-AB95-44E2-A955-6DFFE915E086Q30398268-86D4F7A8-0DB4-48FA-A75C-502B8D1F5BEEQ30407250-1D22AA48-0217-4B0F-A563-AB7903EA0B7AQ30407719-B731C1BD-0C43-4E6E-9FA0-B70AE6BDCE3AQ30415224-245136D3-9116-4356-8DC4-91DFCB583EABQ30427049-F5819AD3-0B97-483B-89CA-8AEA2D074FEBQ30431394-9E0144C6-8277-4FA3-B82D-90B5843DE9D5Q34389114-3FBC971A-80A5-4577-B64A-7FEFA7CFCC14Q34483638-5D573105-72D8-4BD3-B25D-3C08C3D46156Q35512344-15D97E8D-846A-4A6F-978E-B3F7322A6069Q36172477-47B50753-D58F-43BD-B72A-580305103DE6Q36924693-C5590745-8F47-4FE9-AAA8-BAF64C05438BQ38084212-325E83E8-850A-4722-A3B5-80E4701E7F70Q38349536-FCD5CC61-A2CA-497A-A4F9-ECCFC6ACFDD1Q38790740-C528D5A6-8F73-4549-A35C-5B2903E5B034Q39592863-E9C7C804-145B-44B1-99FF-B29232CB94BEQ39907415-C19A3056-957F-41AD-9844-626407FC2082Q40152480-E27E262F-6D9B-4723-B355-BC3D608EA8BCQ40748977-87F71327-5E25-4B68-8DD1-355AB22A04EBQ40970018-7079F2DE-4BE7-4BBC-90D8-07D9ED0E75B0Q42166088-E3085DC7-52F6-4A28-A028-067F7834AF5AQ44528548-76DCCC98-C0DE-4C47-8165-CD6692AFC5F6Q44857539-B3902C74-E000-46CD-862D-336FECA28CDAQ48105726-3B763150-58D7-4A93-B8AB-ED2758576DCFQ53351375-6D887607-E9B1-4243-83F9-4DB5E45C6018Q57105880-9194C7DA-A43E-4804-B246-7B39F36804FF
P2860
Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza.
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Enteric absorption and pharmac ...... ith pandemic (H1N1) influenza.
@ast
Enteric absorption and pharmac ...... ith pandemic (H1N1) influenza.
@en
type
label
Enteric absorption and pharmac ...... ith pandemic (H1N1) influenza.
@ast
Enteric absorption and pharmac ...... ith pandemic (H1N1) influenza.
@en
prefLabel
Enteric absorption and pharmac ...... ith pandemic (H1N1) influenza.
@ast
Enteric absorption and pharmac ...... ith pandemic (H1N1) influenza.
@en
P2093
P2860
P50
P356
P1476
Enteric absorption and pharmac ...... ith pandemic (H1N1) influenza.
@en
P2093
Amarnath Pisipati
Anand Kumar
Daniel S Sitar
Salmaan Kanji
Stéphane Ahern
P2860
P304
P356
10.1503/CMAJ.092127
P407
P577
2010-02-16T00:00:00Z